Routes of
administration Intravenous | ATC code V04CC03 (WHO) | |
 | ||
AHFS/Drugs.com Micromedex Detailed Consumer Information Pregnancy
category US: B (No risk in non-human studies) Legal status UK: Available on a named-patient basis
US: ℞-only Synonyms 1-De(5-oxo-L-proline)-2-de-L-glutamine-
5-L-methioninecaerulein, 3-[[2-[[2-[[2-[[2-[[2-[(2-amino-3-carboxy-propanoyl)
amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4-
methylsulfanyl-butanoyl]amino]acetyl]amino]-3-
(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanyl-
butanoyl]amino]-3-[(1-carbamoyl-2-phenyl-ethyl)
carbamoyl]propanoic acid | ||
Sincalide (INN) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin, and also known as CCK-8.
Common adverse effects following administration include abdominal discomfort and nausea. These effects are more pronounced following rapid infusion.
Indications
Sincalide may be used to stimulate gallbladder contraction, as may be assessed by contrast agent cholecystography or ultrasonography, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals. It can also be used to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology. In some instances it is used to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and-extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.